

Human Monocomponent Insulin for the doctors and nurses of tomorrow



Insulin treatment today may lead to antibody problems in the future, a persuasive argument in favour of using the least immunogenic insulin.

Novo's human insulin is identical to the hormone they are unable to make for themselves.

There are three U100 formulations, Human Actrapid, Human Monotard and Human Protaphane all made to the same exacting standard of Monocomponent purity.

As a result of their structure and purity, Novo Human Monocomponent insulins have been shown to cause 'fewer antibodies than even the purest animal insulins.'



Prescribing Information

Human Actrapid® 100 i.u./ml ▼

Human Insulin (emp) (Neutral Insulin Injection)

Human Monotard® 100 i.u./ml ▼

Human Insulin (emp) (Insulin Zinc Suspension)

Human Protaphane® 100 i.u./ml ▼

Human Insulin (emp) (Isophane Insulin Injection)

Indications The treatment of insulin-requiring diabetic patients.

Human Actrapid is indicated for diabetics who require a quick and intense-acting insulin, particularly in emergencies such as diabetic hyperglycaemic coma, during surgery and severe infections in diabetics, and in the management of pregnant diabetics. Human Monocomponent insulin may be advantageous in the treatment of insulin-induced fat atrophy, insulin allergy, insulin resistance and when intermittent short-term therapy is required.

Dosage and Administration The dosage of Human Actrapid, Human Monotard and Human Protaphane is determined by the physician according to the needs of the patient.

Human Actrapid may be given by injection or infusion, subcutaneously, intramuscularly or intravenously.

Human Monotard and Human Protaphane should be well shaken and given immediately by subcutaneous or intramuscular injection. They may be given twice, or occasionally once daily. Human Actrapid may be admixed with Human Monotard or Human Protaphane in the syringe and injected immediately. U100 insulins must only be used with U100 syringes. Peristaltic pumps (roller pumps) are not suitable for use with Human Actrapid due to the risk of precipitation. Human Monotard and Human Protaphane must not be used in insulin infusion pumps.

Contra-Indications, Warnings and Adverse Effects

Insulin is contra-indicated in hypoglycaemia. In the event of an overdose, glucose should be given orally if the patient is conscious. The unconscious patient should be treated with glucose intravenously and glucagon may be administered intramuscularly or subcutaneously. On transfer from porcine monocomponent insulins or other highly purified porcine insulins to Human Monocomponent insulin, no change in dosage is anticipated other than the routine adjustments made in order to maintain stable diabetic control. However, patients transferred from conventional (predominantly bovine) insulins may require a dosage adjustment. The addition of corticosteroids, oral contraceptives or thyroid hormone replacement therapy is likely to lead to an increase in insulin requirements. The addition of a beta-adrenergic blocking agent or a monoamine oxidase inhibitor (MAOI) may also necessitate an adjustment of insulin dosage. Lipodystrophy, insulin resistance and hypersensitivity reactions have been associated with insulin therapy, but the incidence and severity of these unwanted effects is minimal with Human Monocomponent insulins. Severe local or generalised allergic reactions require immediate treatment and, in some cases, desensitisation may also be necessary.

Pack Size and Basic NHS Price (UK only)

All Human Monocomponent insulins
10ml vials £7.88

Product Licence Numbers

Human Actrapid 100i.u./ml 4668/0003

Human Monotard 100i.u./ml 4668/0006

Human Protaphane 100i.u./ml 4668/0007

Product Licence Holder:

Novo Industri A/S, Novo Alle, DK-2880 Bagsvaerd,

Copenhagen, DENMARK.

Sole Distributor:

Farillon Ltd., Bryant Avenue, Romford, Essex RM30PJ.

Tel: Ingrebourne 71136

References

1. Scherthaner G, et al. Immunogenicity of Human Insulin (Novo) or Pork Monocomponent Insulin in HLA-DR Typed Insulin-dependent Diabetic Individuals. In: International Symposium on Human Insulin, Eds Karam J H, Elzawier D D, Diabetes Care: 6 (Suppl 1): 43-48.

NOVO INDUSTRIAS

Copenhagen, Denmark.

Further information is available on request from:

NOVO LABORATORIES LTD

Ringway House, Bell Road, Dunsdon Hill East,

Basingstoke, Hampshire RG24 0QN.

Tel: Basingstoke (0256) 55055.



Novo Human Monocomponent Insulin
for diabetic children with a full life
ahead of them

whatever his mum worries about, it won't be his asthma.

Regular Intal therapy can give real protection from asthmatic attacks, minimising both incidence and severity.¹

With reduced anxiety, there is less need to resort to symptomatic medication such as bronchodilators² or oral corticosteroids³

Current investigations suggest
that these improvements are accompanied by a reduction
of cellular infiltration in bronchial mucus.⁴
Which indicates that Intal therapy may have a beneficial effect
on the underlying pathology of asthma.

Because the Intal routine can be integrated unobtrusively
into the day's normal activities, the asthmatic child can get on
with the real business of growing up.

He'll be more at ease with his condition.
And so will his parents, teachers and friends.

References:

1. Bernstein, L. et al., *J. Allergy Clin. Immunol.*, (1972), **50**, 4, 235-245.
2. Rubin, A. E., Alroy, G. & Spitzer, S., *Curr. Med. Res. Opin.*, (1983), **8**, 553.
3. Toogood, J. H. et al., *J. Allergy Clin. Immunol.*, (1973), **52**, 6, 334-345.
4. Diaz, P. et al., *Thorax*, (1983), **38**, 9, 702-703.

Presentation Intal and Intal Compound Spincaps* both contain 20mg Sodium Cromoglycate B.P. Isoprenaline Sulphate (0.1mg) is included in Intal Compound Spincaps. The powder from Spincaps is inhaled using the Spinhaler* or Halermatic* which work by the patient's inspiratory effort. The Intal Inhaler is a metered dose pressurised aerosol delivering 200 inhalations of 1.0mg Sodium Cromoglycate. Intal Nebuliser Solution is presented in ampoules each containing 20mg Sodium Cromoglycate in 2ml sterile aqueous solution. **Indication** Preventive treatment of bronchial asthma, including the prevention of exercise-induced asthma. **Dosage and Administration** Adults and children: the normal dose is one Spincap (Intal or Intal Compound) two puffs of Inhaler or one ampoule of Nebuliser Solution to be inhaled four times daily. Intal Nebuliser Solution is administered from a suitable power-operated nebuliser. Since Intal therapy is preventive it is important that the patient is instructed to maintain regular dosage as distinct from intermittent use to relieve symptoms. **Side effects** With the powder formulations of Intal, irritation of the throat and trachea may occur in patients sensitive to the inhalation of dry powder. Although it has not been reported for the Inhaler or Nebuliser Solution, rare cases of severe bronchospasm have occurred following the administration of Intal Spincaps using a Spinhaler. **Precautions** For Intal Compound the precautions normally applying to isoprenaline should be observed. **Withdrawal of therapy** This should be done progressively over one week. Symptoms may recur. Any previous steroid therapy should be reinstated prior to the withdrawal of Intal. **Basic NHS Cost and Product Licence Number** Intal (per 100 Spincaps) £10.07 PL0113/5022. Intal Compound (per 100 Spincaps) £8.19 PL0113/5023. Intal Inhaler (per 200 inhalations) £10.95 PL0113/0080. Nebuliser Solution (per 48 ampoules) £8.20 PL0113/0068. Fisons plc—Pharmaceutical Division, Loughborough, Leicestershire LE11 0BB. *Registered Trade Mark © Fisons plc



Trust

Intal[®] Inhaler
SODIUM CROMOGLYCATE B.P.
for firm control of asthma

Monatsschrift Kinder- heilkunde

Organ der
Deutschen Gesellschaft
für Kinderheilkunde

132. Band
Heft 9
September 1984

Springer-Verlag
Berlin Heidelberg New York Tokyo

		Thema des Monats	This Month's Topic
		Stationäre, tagesklinische und ambulante Betreuung chronisch kranker Kinder	The Care of Chronically Ill Children in Hospital, Day Hospital, and Out Patient Clinic 623
D. Niethammer		Stationäre, tagesklinische und ambulante Betreuung krebskranker Kinder	The Care of Children with Cancer in Hospital, Day Hospital, and Out-Patient Clinic 624
J. Stoermer		Ambulante Betreuung herzkranker Kinder	Out-Patient Care in Pediatric Cardiology 628
G. Neuhäuser		Stationäre, tagesklinische und ambulante Betreuung chronisch kranker Kinder	The Care of Chronically Ill Children in Hospital, Day-Hospital, and Out-Patient-Clinic 631
		Neuropädiatrische Gesichtspunkte	Neuropediatric Aspects 631
P. Hürter		Die stationäre und ambulante Langzeitbetreuung diabetischer Kinder und Jugendlicher und ihrer Eltern	Hospital and Long Term Care of Diabetic Children and Adolescents and Their Parents 635
U. Stephan		Stationäre, tagesklinische und ambulante Betreuung lungenkranker Kinder	The Care of Children with Lung Disease in Hospital, Day-Hospital and Out Patient Clinic 640
G. Hauptmann, O. Mack		Scheitert die Einführung kindgerechter Behandlungsmethoden an fehlender pflegesatzrechtlicher Absicherung?	Will Child-Orientated Therapy be Prevented by the Lack of Appropriate Modifications in the Mode of Payment by the National Health Service and Other Health Insurance Companies? 643
		Pädiatrie aktuell	Trends in Paediatrics 644
		Was hat das Kind?	What's Wrong with the Child? 645
		Aus Klinik und Forschung Originalien	Clinic and Research Originals
C. Mietens, B. Lütkemeyer, S. Köhler		Epidemiologie und Symptomatik der stenosierenden Laryngotracheitis (Pseudocroup) bei 1322 stationären Patienten in Bochum im Verlauf der letzten 17 Jahre	Epidemiology and Symptomatology of Infectious Croup (Stenosing Laryngotracheitis) in 1322 Hospitalized Patients in Bochum During the Last 17 Years 646
E.-G. Lindenschmidt, H. J. Siemens, S. Beck, T. Schwartz, R. Grüttner, R. Lauf		Vergleichende Untersuchungen über das Rotavirusyndrom nach Infektion mit Humanrotavirus der Subgruppe 1 oder 2	No Difference in Severity of Gastroenteritis Caused by Rotavirus Subgroup Antigen 1 or 2 654
T. Morgenstern, K. H. Niessen, M. Teufel		Stellenwert der Isoamylasen in der Diagnostik einer exokrinen Pankreasinsuffizienz im Kindesalter	Diagnostic Value of Serum Amylase Isoenzymes in Children with Exocrine Pancreatic Insufficiency 661
F. Lachner, W. Marget		Bakterielle Adhäsion an Bukkal epithelien als Dauerindikator für rekurrende Harnwegsinfektionen	Bacterial Attachment to Buccal Epithelial Cells as a Permanent Indicator of Recurrent Urinary Tract Infection 666
J. Lopez Sastre, G. D. Coto, A. Ramos, L. F. Fanjul, M. A. Hernandez, M. Crespo		Beitrag zum Studium des C-reaktiven Proteins - bestimmt durch die radiale Immundiffusion und verglichen mit der Latex-Agglutinations-Methode	A Contribution to the Study of C-reactive Proteins - Essayed by Radial Immunodiffusion in Comparison to Latex-Agglutination-Method 671
P. Allhoff, B. Rennen-Allhoff		Probleme entwicklungsdiagnostischer Verfahren	Problems with Developmental Scales in Pediatrics 674
		Der interessante Fall	The Interesting Case
D. Gekle, R. Wartha, W. Romen		Irreversibles Nierenversagen nach Minimal-Changes Nephrose	Irreversible Renal Failure After Minimal Changes Nephrosis 680
H. Bachmann		„Hypertonie“ durch Blutdruckmessung mit zu schmaler Manschette	Small Cuff as a Cause of „Hypertension“ in Children 683
		Wußten Sie schon?	Do You Know?
		<i>Aus der Klinik — für die Klinik</i>	<i>Clinical Tips for Clinicians</i>
H. Schachinger, H.-D. Frank, Hj. Schmid		Klinisches Management der bronchopulmonalen Dysplasie	Clinical Management of Bronchopulmonary Dysplasia 685
		Auflösung der Fragen „Was hat das Kind?“	Solutions and Commentary of the Questions "What's Wrong with the Child?" 682
		Laudationes	Laudationes
K. H. Schäfer		Professor Dr. Helmut Müller 75 Jahre	688
H. Wolf		Professor Dr. Hanns Lohr 60 Jahre	688
		Neue Bücher	New Books 689
		Erratum	Erratum 689
		Tagungskalender	Forthcoming Meetings 690
		Zusammenfassung der Vorträge der 80. Tagung der Deutschen Gesellschaft für Kinderheilkunde, 16. – 19. September 1984 in Tübingen	691
		Für die Dokumentation	Documentation A 58

ABC OF COMPUTING

A J ASBURY

Although computers are being widely used in medicine, their possibilities and limitations are still not clear to many potential users. This book, aimed at the non-expert, describes some of the uses of computers in medicine; because most doctors' involvement will be indirect, liaising with computer experts rather than designing systems themselves, the book concentrates on concepts rather than detailed descriptions of how computers work. It provides a useful introduction for the doctor who wants to know how computers can contribute to his practice of medicine.

Price: Inland £5.75;
Overseas £8.00*/USA \$14.00*
(Inland £5.25;
Overseas £7.50*/USA \$13.00*
to BMA members)

**including air mail postage*

Payment must be enclosed with order

Order your copy now
From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller

A TRULY REMARKABLE CEPHALOSPORIN

FORTUM

ceftazidime

PRESCRIBING INFORMATION

Presentation. Fortum for Injection is supplied in vials containing 500mg, 1g and 2g ceftazidime (as pentahydrate) with sodium carbonate.

Uses. Fortum is a bactericidal cephalosporin antibiotic which is resistant to most beta-lactamases and is active against a wide range of Gram-positive and Gram-negative bacteria.

It is indicated for the treatment of single infections and for mixed infections caused by two or more susceptible organisms. Fortum, because of its broad antibacterial spectrum, may be used alone as first choice drug, pending sensitivity test results.

Dosage and administration. The usual adult dosage is in the range 1g to 6g i.m. or i.v. per day and by the i.p. route 125-250mg/2 litre of dialysis fluid (see Data Sheet for details).

Contra-indication. Fortum is contra-indicated in patients with known hypersensitivity to cephalosporin antibiotics.

Precautions. Cephalosporins may, in general, be given safely to patients who are hypersensitive to penicillins. Care is indicated in patients who have experienced an anaphylactic reaction to penicillin.

Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with nephrotoxic drugs. Clinical experience with Fortum has shown that this is not likely to be a problem at the recommended dose levels. Reduce dosage when renal function is impaired (see Data Sheet).

As with all drugs, Fortum should be administered with caution during the early months of pregnancy and in early infancy. Fortum is excreted in human milk in low concentrations.

Fortum does not interfere with enzyme-based tests for glycosuria. Slight interference with copper reduction methods may be observed. Fortum does not interfere in the alkaline picrate assay for creatinine.

Fortum and aminoglycosides should not be mixed in the same giving set or syringe. As with other broad spectrum antibiotics, prolonged use of Fortum may result in the overgrowth of non-susceptible organisms (e.g., *Candida*, *Enterococci*) which may require interruption of treatment or adoption of appropriate measures.

Side effects. Fortum is generally well tolerated with only infrequent adverse reactions, e.g., pain and/or inflammation after i.m. administration and phlebitis and/or thrombophlebitis after i.v. administration, rashes, fever, pruritus, gastro-intestinal disturbances, headache, dizziness, paraesthesiae and bad taste. Transient changes in laboratory values may occur including: eosinophilia, a positive Coombs' test, thrombocytosis and slight rises in hepatic enzymes.

Basic NHS cost (exclusive of VAT). The basic NHS cost of Fortum is £9.90 per gram. Available in packs of: 5 x 500mg, 5 x 1g and 5 x 2g vials and an infusion pack of 5 x 2g vials.

Product licence numbers. 500mg: 0004/0292. 1g: 0004/0293. 2g: 0004/0294.

References

1. Morgan G, Duerden B I, Lilleyman J S. J. of Antimicrob Chemother 1983; 12 (Supp. A): 347-351.
2. Snelling S, Hart C A, Cooke R W I. J. of Antimicrob Chemother. 1983; 12 (Supp. A): 353-356.
3. David T J, Phillips B M, Connor P J. J. of Antimicrob Chemother 1983; 12 (Supp. A): 337-340.

Further information is available on request from:

Glaxo

Glaxo Laboratories Limited, Greenford, Middlesex UB6 0HE

Fortum is a Glaxo trade mark

Hospital antibiotics created in Britain by



**A TRULY
REMARKABLE
CEPHALOSPORIN**

FORTUM

ceftazidime

Proven equal to standard
broad spectrum combination therapy^{1,2,3}
Fortum provides first line treatment without
aminoglycoside toxicity.

*Hospital antibiotics created in Britain by **Glaxo***

PEDIATRIC RESEARCH

Volume 18, No. 9

September 1984

Contents

- The Protective Effect of Carnitine in Human Diphtheric Myocarditis
Antônio Carlos Marques Figueiredo Ramos, Paulo Roberto P. Elias, Louis Barrucand, and José Ananias Figueira Da Silva
- Regulation of Upper Airway Maintaining Muscles during Progressive Asphyxia
O. P. Mathew, B. T. Thach, Y. K. Abu-Osba, R. T. Brouillette, and J. L. Roberts
- Differences in Thromboxane Production between Neonatal and Adult Platelets in Response to Arachidonic Acid and Epinephrine
Marie J. Stuart, Jon Dusse, David A. Clark, and Ronald W. Walenga
- The Influence of Early Malnutrition on Subsequent Behavioral Development. IV. Soft Neurologic Signs
Janina R. Galler, Frank Ramsey, Giorgio Solimano, L. Thomas Kucharski, and Robert Harrison
- Hypoxia Stimulates Prostacyclin Synthesis by Neonatal Lungs
Robert S. Green and Charles W. Leffler
- Vasopressin Concentration in Amniotic Fluid as an Index of Fetal Hypoxia. Mechanism of Release in Sheep
Raymond I. Stark, Salha S. Daniel, M. Kazim Husain, Ulana M. Sanocka, Alan B. Zubrow, and L. Stanley James
- Indomethacin and the Cardiopulmonary Adaptations of Transition
Cathy Hammerman and Emile M. Scarpelli
- Growth-related Changes in Oxygen Uptake and Heart Rate during Progressive Exercise in Children
Dan M. Cooper, Daniel Weiler-Ravell, Brian J. Whipp, and Karlman Wasserman
- The Relationship between the Branched Chain Amino Acids and Their α -Ketoacids in Maple Syrup Urine Disease
Selma E. Snyderman, Fred Goldstein, Claude Sansaricq, and Patricia M. Norton
- Some Aspects of Maternal Metabolism Throughout Pregnancy in the Conscious Rabbit
Marc Gilbert, William W. Hay, Jr., Robert L. Johnson, and Frederick C. Battaglia
- Vasodilators and Ventricular Septal Defect. Comparison of Prazosin, Minoxidil, and Hydralazine in a Chronic Lamb Model
Mark M. Boucek, Richard Chang, and David P. Synhorst
- Studies of Lipids, Lipoproteins, and Apolipoproteins in Menkes' Disease
P. R. Blackett, D. M. Lee, D. L. Donaldson, J. D. Fesmire, W. Y. Chan, J. H. Holcombe, and O. M. Rennert
- Pulmonary Antioxidant Enzyme Maturation in the Fetal and Neonatal Rat. II. The Influence of Maternal Iron Supplements upon Fetal Lung Catalase Activity
A. Keith Tanswell and Bruce A. Freeman
- Cardiovascular Changes in Group B Streptococcal Sepsis in the Piglet. Response to Indomethacin and Relationship to Prostacyclin and Thromboxane A_2
Beatriz Runkle, Ronald N. Goldberg, Murray M. Streitfeld, Martin R. Clark, Elena Buron, Emmalee S. Setzer, and Eduardo Bancalari



Tegretol[®] making epilepsy easier to live with

carbamazepine BP

Tegretol[®]

Indications Epilepsy (generalised tonic-clonic and partial seizures), trigeminal neuralgia. **Dosage in epilepsy** Use a gradually increasing dosage scheme, adjusting to patient's needs. Adults: 100-200mg once or twice daily, increasing slowly up to 800-1,200mg daily; in some cases 1,600mg daily may be necessary. Children: up to 1 year old, 100-200mg daily; aged 1-5 years, 200-400mg daily; aged 5-10 years, 400-600mg daily; aged 10-15 years, 600-1,000mg daily. It may be helpful to monitor plasma drug levels: optimum therapeutic range is 3-10µg/ml (13-42µmol/l). **Dosage in trigeminal neuralgia** Begin with small doses, using 100mg tablets or syrup, and increase gradually until satisfactory therapeutic response is obtained; 200mg 3-4 times daily is generally sufficient to maintain pain-free state. **Side-effects** Dizziness and diplopia (usually dose-dependent), less frequently drowsiness, dry mouth, diarrhoea, nausea and vomiting. Generalised erythematous rash, disappearing on cessation of therapy. Isolated reports of oedema, hyponatraemia, exfoliative dermatitis, leucopenia, thrombocytopenia, agranulocytosis, aplastic anaemia, cholestatic jaundice and acute renal failure. Blood count should be checked in early stages of treatment. **Precautions** Caution in patients taking oral anticoagulants or requiring oral contraception. In pregnancy, potential benefits of Tegretol must be weighed against potential hazards. Do not administer with, or within two weeks of cessation of, MAOI therapy. In rats treated with carbamazepine for two years, incidence of liver tumours increased (no evidence of significant bearing on the therapeutic use of the drug). Serum folic acid levels should be observed during anticonvulsant therapy. **Contra-indications** Previous drug sensitivity to Tegretol. Do not administer to patients with atrioventricular conduction abnormalities unless paced. **Packs** Tablets of 100mg (PL0001/5027) basic NHS price £2.90 per 100, £13.95 per 500; tablets of 200mg (PL0001/5028) £5.38 per 100, £25.93 per 500; tablets of 400mg (PL0001/0088) £10.58 per 100; syrup 100mg/5ml (PL0001/0050) £5.17 per 300ml bottle. * denotes registered trademark. **Geigy**

Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex.